These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25384074)

  • 1. Dopamine agonist modifies cortical activity in Parkinson disease: a functional neuroimaging study.
    Lucetti C; Diciotti S; Baldacci F; Tessa C; Ginestroni A; Cecchi P; Paoli L; Del Dotto P; Ceravolo R; Mascalchi M; Bonuccelli U
    Clin Neuropharmacol; 2014; 37(6):166-72. PubMed ID: 25384074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease.
    Tessa C; Diciotti S; Lucetti C; Baldacci F; Cecchi P; Giannelli M; Bonuccelli U; Mascalchi M
    Parkinsonism Relat Disord; 2013 Feb; 19(2):265-8. PubMed ID: 22901957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased and increased cortical activation coexist in de novo Parkinson's disease.
    Tessa C; Lucetti C; Diciotti S; Baldacci F; Paoli L; Cecchi P; Giannelli M; Ginestroni A; Del Dotto P; Ceravolo R; Vignali C; Bonuccelli U; Mascalchi M
    Exp Neurol; 2010 Jul; 224(1):299-306. PubMed ID: 20399207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional MRI study of motor dysfunction in Friedreich's ataxia.
    Akhlaghi H; Corben L; Georgiou-Karistianis N; Bradshaw J; Delatycki MB; Storey E; Egan GF
    Brain Res; 2012 Aug; 1471():138-54. PubMed ID: 22771856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the cerebellum in the control of distal motor activities in patients with akinetic-rigid Parkinson disease].
    Moretti R; Torre P; Antonello RM; Ukmar M; Cazzato G; Pizzolato G
    Recenti Prog Med; 2005 Dec; 96(12):599-603. PubMed ID: 16496744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
    Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
    Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic modulation of the default mode network in Parkinson's disease.
    Delaveau P; Salgado-Pineda P; Fossati P; Witjas T; Azulay JP; Blin O
    Eur Neuropsychopharmacol; 2010 Nov; 20(11):784-92. PubMed ID: 20674286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study.
    Elsinger CL; Rao SM; Zimbelman JL; Reynolds NC; Blindauer KA; Hoffmann RG
    J Int Neuropsychol Soc; 2003 Nov; 9(7):1088-98. PubMed ID: 14738289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dopamine agonists situation in Parkinson disease].
    Barbanoj M; Campos Arillo VM; Giménez-Roldán S; Kulisevsky J; Linazasoro Cristóbalampos G; Luquin Piudo MR; Vela Desojo L
    Rev Neurol; 2001 Dec 1-15; 33(11):1071-93. PubMed ID: 11785037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical motor and sensory cortex activation in attention-deficit/hyperactivity disorder: a functional magnetic resonance imaging study of simple sequential finger tapping.
    Mostofsky SH; Rimrodt SL; Schafer JG; Boyce A; Goldberg MC; Pekar JJ; Denckla MB
    Biol Psychiatry; 2006 Jan; 59(1):48-56. PubMed ID: 16139806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements.
    Mallol R; Barrós-Loscertales A; López M; Belloch V; Parcet MA; Avila C
    Brain Res; 2007 May; 1147():265-71. PubMed ID: 17368575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic modulation of cortical function in patients with Parkinson's disease.
    Mattay VS; Tessitore A; Callicott JH; Bertolino A; Goldberg TE; Chase TN; Hyde TM; Weinberger DR
    Ann Neurol; 2002 Feb; 51(2):156-64. PubMed ID: 11835371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S98-102. PubMed ID: 12211149
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease : a motor fMRI study under controlled conditions.
    Tessa C; Lucetti C; Diciotti S; Paoli L; Cecchi P; Giannelli M; Baldacci F; Ginestroni A; Vignali C; Mascalchi M; Bonuccelli U
    Neuroradiology; 2012 Mar; 54(3):261-8. PubMed ID: 21927866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Within-session and between-session reproducibility of cerebral sensorimotor activation: a test--retest effect evidenced with functional magnetic resonance imaging.
    Loubinoux I; Carel C; Alary F; Boulanouar K; Viallard G; Manelfe C; Rascol O; Celsis P; Chollet F
    J Cereb Blood Flow Metab; 2001 May; 21(5):592-607. PubMed ID: 11333370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional evaluation of cortical motor areas in Amyotrophic Lateral Sclerosis.
    Cosottini M; Pesaresi I; Piazza S; Diciotti S; Cecchi P; Fabbri S; Carlesi C; Mascalchi M; Siciliano G
    Exp Neurol; 2012 Mar; 234(1):169-80. PubMed ID: 22226599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.